论文部分内容阅读
目的探讨培美曲塞联合卡铂治疗晚期非鳞非小细胞肺癌的临床疗效。方法选择收治的104例晚期非鳞非小细胞肺癌患者,随机分为观察组(52例)和对照组(52例)。观察组患者采用培美曲塞联合卡铂治疗,对照组患者采用吉西他滨联合卡铂治疗,比较两组患者的治疗效果。结果治疗后,观察组患者有效率为46.2%,对照组为44.7%,差异无统计学意义(2=1.25,P>0.05),观察组患者不良反应发生率明显低于对照组患者,差异均有统计学意义(均P<0.05),观察组患者的疾病进展时间(TTP)、中位生存时间(MST)和1年生存率分别为(6.2±2.1)个月、(8.9±2.1)个月和51.8%,均明显优于对照组患者,差异均有统计学意义(均P<0.05)。结论培美曲塞联合卡铂治疗晚期非鳞非小细胞肺癌疗效显著,提高了患者生活质量,值得临床推广。
Objective To investigate the clinical efficacy of pemetrexed combined with carboplatin in the treatment of advanced non-squamous non-small cell lung cancer. Methods One hundred and forty-four patients with advanced non-squamous non-small cell lung cancer (NSCLC) were selected and randomly divided into observation group (52 cases) and control group (52 cases). Patients in the observation group were treated with pemetrexed combined with carboplatin, and patients in the control group were treated with gemcitabine combined with carboplatin. The therapeutic effect was compared between the two groups. Results After treatment, the effective rate was 46.2% in the observation group and 44.7% in the control group, with no significant difference (2 = 1.25, P> 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). The time to progression (TTP), median survival time (MST) and 1-year survival rate in the observation group were (6.2 ± 2.1) months and (8.9 ± 2.1) Month and 51.8%, respectively, were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Pemetrexed combined with carboplatin in the treatment of advanced non-squamous non-small cell lung cancer has a significant effect, improving the quality of life of patients, it is worth clinical promotion.